Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nexium Is Part Of Anti-Competitive Plan To Thwart Generic Prilosec, Retailer Suit Against AstraZeneca Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Walgreen’s, Eckerd and Kroger are among the retailers filing suit against AstraZeneca over the launch of the Prilosec follow-on Nexium.

You may also be interested in...



The Price Is Not Right: AstraZeneca Puts Nexium On Sale

Marketing shift will target branded proton pump inhibitors for market share gains rather than generic Prilosec.

The Price Is Not Right: AstraZeneca Puts Nexium On Sale

Marketing shift will target branded proton pump inhibitors for market share gains rather than generic Prilosec.

AstraZeneca’s New Head Of Strategic Planning & Business Development John Goddard: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

AstraZeneca looking to improve how it manages deals, Goddard says.

Topics

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel